Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchCEL-SCI Corporation Announces Strong Biological Rationale for Multikine in Head and Neck Cancer Study
Dec 12, 2024
ViennaBiotechnologyHealthcareHealth Care
Product Description
CEL-SCI Corporation highlights the biological rationale for Multikine, an immunotherapy intended for treating head and neck cancer, in a newly FDA-approved confirmatory registration study. The study will evaluate the effectiveness of Multikine, showcasing prior positive survival outcomes compared to control treatments.
Company Information
Company
CEL-SCI Corporation
Location
Vienna, Illinois, United States
About
CEL-SCI is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company’s lead investigational therapy Multikine completed a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company has received Orphan Drug Status from the FDA. The Company will be commencing a confirmatory trial for Multikine, with enrollment expected to begin in Q4 2024. The Company has operations in Vienna, Virginia, and near Baltimore, Maryland.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment CEL-SCI Corporation ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ViennaBiotechnologyHealthcareHealth Care